MAPLIGHT THERAPEUTICS INC (MPLT)
Health Care · Biotechnology · NASDAQ
MapLight Therapeutics is a clinical-stage biopharmaceutical company developing circuit-specific therapies for serious central nervous system disorders, led by its flagship M1/M4 muscarinic agonist program.
What MAPLIGHT THERAPEUTICS INC does
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on developing circuit-specific pharmacotherapies for debilitating central nervous system (CNS) disorders. Its lead candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic designed for the treatment of schizophrenia and Alzheimer's disease psychosis. The company uses a discovery platform to identify and target neural circuits causally linked to specific disease behaviors.
Recent developments
In July 2026, the company reported positive Phase 2 ZEPHYR trial results for ML-007C-MA in schizophrenia, supporting a planned Phase 3 trial. In August 2026, the company secured $150 million in a private placement to extend its cash runway through 2028 and announced it is pausing investment in preclinical/discovery programs to focus resources on ML-007C-MA.
From MAPLIGHT THERAPEUTICS INC's filing of 2026-08-13.
Themes: CNS disorders, Schizophrenia, Alzheimer's disease psychosis, Autism spectrum disorder, Muscarinic agonists
Fundamentals
- Price$9.15 as of 2026-10-08 close
- Market cap$388M as of 2026-03-19 (share count; price 2026-10-08)
- P/En/a negative earnings
- ROE-35.2% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Beta0.55 as of 2026-09-03
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How MPLT compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How MAPLIGHT THERAPEUTICS INC looks technically
MAPLIGHT THERAPEUTICS INC (MPLT) is trading 56.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 21 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 44, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 28, in oversold territory (below 30). It just made a new 20-day low, breaking below its recent trading range. Trading volume is unusually light — only about 40% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 56.1% below its 200-day average, the long-term trend line — a long-term downtrend | -56.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $11.81 | $11.81 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $20.84 | $20.84 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 29 calendar days ago — the swings before that are what the structure reading is measured on | 29 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 14.22. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 3 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 21 trading days ago — a "death cross", a bearish long-term signal | 21 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 44, with sellers in control | 43.6 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 28, in oversold territory (below 30) | 27.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($8.92 to $11.28) — its "stochastic" reading is 10 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 9.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 38 sessions |
Range
7
| Since a 20-day breakout | it just made a new 20-day low, breaking below its recent trading range | 1 session |
|---|---|---|
| Since a 55-day breakout | it just made a new 55-day low, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $40.43 (set on 2026-07-10) | $40.43 |
| Given back of the 52-week move | not available for this company yet | n/a |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $8.92 (set on 2026-10-06) | $8.92 |
| Above the all-time low | it is 2.6% above its all-time low | +2.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 58th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.8122 between its high and its low — about 8.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.8122 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $8.47 and $12.86 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $8.47 – $10.67 – $12.86 |
| Typical daily range (% of price) | its price moves about 8.9% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.9% |
| Stretch from the 200-day average | it is trading 14.4 daily ranges below its 200-day average price (56.1% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 14.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 40% of its 30-day average | 0.40× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bearish engulfing | 7 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 7 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.6% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.6% |
|---|---|---|
| Open gap | it gapped 64.5% below the previous close 52 sessions ago and has not traded back through the level it left behind at 36.56 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -64.5% |
| Gap filled | a 3.0% gap up opened on 2026-09-30 has been "filled" 6 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 6 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -5.57% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 35.4 percentage points (the stock lost 34.4% while the market gained 1.0%) | -35.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 80.1 percentage points (the stock lost 76.3% while the market gained 3.8%) | -80.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 77.0 percentage points (the stock lost 59.5% while the market gained 17.5%) | -77.0% |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), MACD momentum is positive, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 26% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 135.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -26.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 52% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $19.22 — a volume-weighted average of daily closes over 183 sessions, not a true tick-by-tick VWAP. | -52.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 22% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $11.77 — a volume-weighted average of daily closes over 40 sessions, not a true tick-by-tick VWAP. | -22.3% |
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $14.22.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 17 trading days, since 2026-09-16.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Oversold (14-day RSI below 30) · Broke down to a new 20-day low · Most volatile (6%+ typical daily range) · Stretched far below its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · breakout · volume and relative volume
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$26.54 range $13.00 – $43.00; median $25.00
Analyst estimates, as of 2026-10-03. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MPLT
- Consensus EPS estimate-$1.09 next reporting period, as of 2026-10-03
- Estimate change, 30 days-$0.0045 from -$1.09, on 2026-08-29, 35-day window
- Readings revised upward0% of 6 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company is in the clinical stage and is currently unprofitable, with a history of losses and a reliance on external funding.","The success of the company's business model depends on the clinical and regulatory success of its lead product candidate, ML-007C-MA.","If the company's information technology systems or those of its third-party collaborators are compromised, it could result in significant business disruption, regulatory consequences, and reputational harm."]
Insider activity (SEC Form 4)
6 open-market purchases and 46 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 1 sell ($192660) — 1 selling insider
- Last 90 days · read to 2026-10-046 buys ($66M) · 46 sells ($12M) — 2 buying, 6 selling insiders
- Last 180 days · read to 2026-10-046 buys ($66M) · 126 sells ($28M) — 2 buying, 8 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-16. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about MPLT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding MPLT as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 2,793,279
- Reported value $100,111,119
reported quarterly holdings change (2026-03-31 → 2026-06-30): 2 new, 2 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about MPLT's institutional holders → See what each manager we track holds →
Short interest (FINRA)
MPLT had 3,297,011 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
MPLT had 7.77% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.07 days to cover at the same settlement.
- Reported short interest (shares) 3,297,011
- Short interest (% of shares outstanding) 7.77%
- Prior settlement (shares) 3,426,509
- Reported change -3.78%
- Days to cover (reported) 6.07
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Karuna Therapeutics (acquired by Bristol Myers Squibb)
- Acadia Pharmaceuticals (ACAD)
- Cerevel Therapeutics (acquired by AbbVie)
- Neurocrine Biosciences (NBIX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MPLT vs…
Frequently asked questions
What does MAPLIGHT THERAPEUTICS INC (MPLT) do?
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on developing circuit-specific pharmacotherapies for debilitating central nervous system (CNS) disorders. Its lead candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic designed for the treatment of schizophrenia and Alzheimer's disease psychosis.
What sector is MAPLIGHT THERAPEUTICS INC (MPLT) in?
MAPLIGHT THERAPEUTICS INC (MPLT) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are MAPLIGHT THERAPEUTICS INC's (MPLT) competitors?
Notable peers of MAPLIGHT THERAPEUTICS INC (MPLT) include Karuna Therapeutics (acquired by Bristol Myers Squibb), Acadia Pharmaceuticals, Cerevel Therapeutics (acquired by AbbVie) and Neurocrine Biosciences. This peer set is informational only — not financial advice.
Is MAPLIGHT THERAPEUTICS INC (MPLT) overbought or oversold right now?
MAPLIGHT THERAPEUTICS INC (MPLT) is currently in oversold territory (its 14-day RSI is 28, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MPLT come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.